These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 20451736

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Re: The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
    Griebling TL.
    J Urol; 2011 Apr; 185(4):1279. PubMed ID: 22098960
    [No Abstract] [Full Text] [Related]

  • 4. Harms versus benefits with duration of androgen suppression.
    Nguyen PL.
    Lancet Oncol; 2012 Dec; 13(12):1182-3. PubMed ID: 23151430
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Re: Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer: C. W. Ryan, D. Huo, L. M. Demers, T. M. Beer and L. V. Lacerna. J Urol 2006; 176: 972-978.
    Gilbert SM, Dunn RL, Wei JT.
    J Urol; 2007 Apr; 177(4):1584-5; author reply 1585. PubMed ID: 17382782
    [No Abstract] [Full Text] [Related]

  • 7. The opportunity cost of androgen suppression in locally advanced prostate cancer.
    Gray PJ, Efstathiou JA, Shipley WU.
    Asian J Androl; 2013 May; 15(3):356-7. PubMed ID: 23435474
    [No Abstract] [Full Text] [Related]

  • 8. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.
    J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Annual zoledronic acid: is less more?
    Higano CS.
    J Clin Oncol; 2007 Mar 20; 25(9):1026. PubMed ID: 17369565
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
    Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, Vogelzang NJ.
    BJU Int; 2007 Jul 20; 100(1):70-5. PubMed ID: 17552955
    [Abstract] [Full Text] [Related]

  • 14. Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
    Hershman D, Narayanan R.
    Curr Oncol Rep; 2004 Jul 20; 6(4):277-84. PubMed ID: 15161581
    [Abstract] [Full Text] [Related]

  • 15. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
    Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR.
    J Clin Oncol; 2007 Mar 20; 25(9):1038-42. PubMed ID: 17369566
    [Abstract] [Full Text] [Related]

  • 16. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.
    Wadhwa VK, Weston R, Parr NJ.
    BJU Int; 2010 Apr 20; 105(8):1082-8. PubMed ID: 19912210
    [Abstract] [Full Text] [Related]

  • 17. Bone Health in Men with Prostate Cancer: Review Article.
    A M El Badri S, Salawu A, Brown JE.
    Curr Osteoporos Rep; 2019 Dec 20; 17(6):527-537. PubMed ID: 31760582
    [Abstract] [Full Text] [Related]

  • 18. [Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].
    Miki T, Okihara K.
    Nihon Rinsho; 2007 Nov 28; 65 Suppl 9():632-5. PubMed ID: 18161177
    [No Abstract] [Full Text] [Related]

  • 19. Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence?
    Reddy SV, Gupta SK.
    Singapore Med J; 2012 Mar 28; 53(3):e52-4. PubMed ID: 22434305
    [Abstract] [Full Text] [Related]

  • 20. Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Pitts WR.
    J Urol; 2003 Dec 28; 170(6 Pt 1):2392-3; author reply 2393-4. PubMed ID: 14634434
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.